Professor Bernd Möbius is a leading academic in Phonetics and Phonology at the Department of Language Science and Technology, Saarland University. His research bridges phonetic theory with speech technology applications, focusing on text-to-speech systems, prosody modeling, and computational simulations of speech processes. Current research projects: DFG SFB 1102, C1: Information density and phonetic structure predictability DFG SFB 1102, C4: Slavic intercomprehension and surprisal theory (INCOMSLAV) Research Themes: Key areas include text-to-speech synthesis, speech prosody analysis, experimental methods in speech production/perception, information density in phonetics, and cross-linguistic studies of Slavic-Germanic languages. Scientific Contributions: Recent work explores Parkinson-induced dysarthria detection, breath noise acoustics, surprisal-driven speech behaviors, multilingual BERT models for idiomaticity, and perceptual consequences of acoustic adjustments.
Dr. Jimeng Sun is a Health Innovation Professor at the Siebel School of Computing and Data Science and Carle Illinois College of Medicine at the University of Illinois Urbana-Champaign. Co-founder of Keiji AI , he leads groundbreaking research at the intersection of artificial intelligence and healthcare, actively deploying clinical AI systems and developing frameworks like PyHealth and Therapeutics Data Commons . His research spans four major areas: Clinical AI Systems : Developing interpretable models (e.g., RETAIN) for patient similarity, temporal event prediction, medication recommendation, and clinical outcome forecasting Drug Discovery : Creating molecular optimization frameworks, drug-target interaction models, and AI-driven platforms Clinical Trials : Pioneering patient-trial matching, outcome prediction, and optimization frameworks using deep learning and graph neural networks Biosignal Analysis : Advancing sleep staging, seizure classification, and automated EEG/Cardiac monitoring systems With over 500 top-tier publications (including in Nature , NEJM AI , and leading AI conferences) and an h-index of 99, his work has been recognized with the Top 100 AI Leaders in Drug Discovery and Advanced Healthcare award. He maintains active collaborations with institutions like Massachusetts General Hospital , Medidata Solutions , and OSF Healthcare . His recent publications reveal a strong focus on: Reinforcement learning applications in medical data analysis Large language model adaptation for clinical tasks Knowledge graph integration with AI systems Synthetic data generation for healthcare Multi-modal learning in clinical contexts Explainable AI for medical applications Dr. Sun's lab ( Sunlab ) emphasizes practical impact over theoretical work, actively collaborating with hospitals and healthtech companies. He welcomes contributions from clinicians, researchers, and industry partners through initiatives like his AI for Health webinar series .
Associate Professor Adam Irwin is an NHMRC Emerging Leadership Fellow and Associate Professor in Infectious Diseases at the University of Queensland (UQ) and Queensland Children’s Hospital. He holds positions within the UQ Centre for Clinical Research, Faculty of Health, Medicine and Behavioural Sciences. His work focuses on early sepsis recognition, antimicrobial stewardship, and pediatric infectious diseases. Dr. Irwin completed his medical degree at the University of Birmingham and his PhD in 2016 from the University of Liverpool’s Institute of Infection and Global Health. He has led initiatives like the Queensland Paediatric Sepsis Program, recognized with a Global Sepsis Alliance Award and Queensland Health Excellence Awards. His research spans sepsis pathway implementation, antimicrobial resistance trends, and rapid diagnostic tools. Notable grants include NHMRC funding for studies on multi-drug resistant infections and Children’s Hospital Foundation support for genomics and antimicrobial stewardship projects. He supervises PhD candidates in areas like bloodstream infections and molecular diagnostics. Dr. Irwin collaborates across institutions, contributing to projects such as the RAPIDS Study Group and the PAEDS surveillance network. Awards include the NHMRC Emerging Leadership Fellowship and recognition for sepsis program excellence. His work emphasizes translating research into clinical practice, improving outcomes for critically ill children through evidence-based protocols and innovative diagnostics.
Laura Elo serves as Professor of Computational Medicine and Head of the Medical Bioinformatics Centre at the University of Turku, Finland. She concurrently holds the position of Research Director at Turku Bioscience Centre and acts as InFLAMES Flagship Contact, driving interdisciplinary biomedical research initiatives. Her academic foundation includes a PhD in Applied Mathematics (2007) and Adjunct Professorship in Biomathematics (2011), establishing her quantitative expertise before transitioning into biomedical applications. Her research program focuses on transforming molecular and clinical datasets through statistical modeling and advanced machine learning . Key thrusts include robust computational tools for proteome/epigenome analysis, AI-driven digital health diagnostics, and computational systems immunology for immune-mediated diseases. This work directly addresses challenges in reproducibility and scalability of high-throughput biotechnology data. Analysis of her recent publications reveals dominant themes in type 1 diabetes biomarker discovery , multi-omics integration , and immune system modeling , with strong emphasis on clinical translation through collaborations with experimental and medical teams. Her scientific recognition includes: JDRF Career Development Award Professor Elo actively trains MSc/PhD students and postdoctoral fellows while leading major research initiatives including ERC grants. Her teaching portfolio spans Bioinformatics Journal Club, AI in Diagnostics, and Systems Biology courses. The Elo Lab (https://elolab.utu.fi) operates as a hub for computational biomedicine, developing open-source tools like CellRomeR while maintaining close ties with Turku Bioscience Centre's experimental facilities for validating computational predictions in immunology and metabolic disease contexts.
Prof. Paul Stupple is a Professor of Medicinal Chemistry at Monash University, Australia, with over 20 years' experience in pharmaceutical industry and academia. He holds leadership roles at Canthera Discovery and manages the Australian Translational Medicinal Chemistry Facility. His expertise lies in small molecule drug discovery, particularly targeting cancer therapies and epigenetic regulators. Affiliations: Monash University, Faculty of Pharmacy and Pharmaceutical Sciences Canthera Discovery (Director, Medicinal Chemistry) Education: BA and DPhil in Chemistry from the University of Oxford (1992–1999). Early career at Pfizer as a medicinal chemistry leader, delivering 6 clinical candidates. Key contributions include: Licensing deals with Merck (2016) and Pfizer (2018) for preclinical projects Leading the Cancer Therapeutics CRC's medicinal chemistry program Research Interests: Small molecule drug discovery focused on histone acetyltransferase inhibitors, cancer therapeutics, and epigenetic modulation. Notable projects include development of KAT6A/B inhibitors for ER+ breast cancer and STING agonists for immunotherapy. Grants/Projects: Principal Investigator for major initiatives like MedChem Australia (2023–2028) and drug target identification platforms. Collaborates widely with institutions like WEHI and University of Sydney. Over 28 peer-reviewed publications spanning 1997–2025. Labs/Teams: Oversees the Australian Translational Medicinal Chemistry Facility, a key resource for drug discovery in Australia.
Dr. Vakil Takhaveev is a Lecturer at ETH Zurich's Department of Health Sciences and Technology, within the Institute of Food, Nutrition and Health. His research focuses on DNA damage mechanisms, aging, cancer, and neurodegeneration, with particular emphasis on developing novel DNA-damage-sequencing methods like click-code-seq and TRABI-Seq . He investigates anticancer drug action (e.g., trabectedin), aging clocks using DNA oxidation profiling, and stress-induced carcinogenesis. His work integrates multi-omics approaches and advanced sequencing techniques. Research Directions: Novel DNA-Damage-Sequencing Methods: Developed click-code-seq and TRABI-Seq for genomic mapping of DNA lesions and repair dynamics. Anticancer Drug Action: Explored mechanisms of trabectedin and other chemotherapeutics, linking DNA repair vulnerabilities to therapy resistance. Aging Clocks: Created DNA oxidation-based biomarkers for biological aging using genome-wide profiling in human and mouse models. Stress-Induced Pathologies: Studies metabolic and DNA damage links to early tumorigenesis and neurodegeneration. Awards & Recognition: 2025 Public Award Winner in PIs of Tomorrow competition 2024 ETH Zurich Career Seed Award Best presentation awards (Swiss Chemical Society, American Chemical Society) Grants & Collaborations: Impetus grants for aging clock development Swiss Chemical Society and American Chemical Society fellowships Labs & Teams: Leads research on DNA damage and aging mechanisms at ETH Zurich, collaborating with international groups in oncology and toxicology.
Cristian Gómez Canela is a Full Professor in the Department of Analytical and Applied Chemistry at the School of Engineering, Ramon Llull University (IQS). He serves as Coordinator of the Master's Degree in Analytical Chemistry and is an active member of the Catalan Chemical Society (SCQ), representing SCQ in EuChems-EYCN. His academic journey includes a PhD in Chemistry from the University of Barcelona (2014), followed by postdoctoral research at IDAEA-CSIC and King's College University. Dr. Gómez Canela's research focuses on environmental analytical chemistry, particularly the optimization and validation of analytical methods based on liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) and high-resolution mass spectrometry (HRMS) for determining organic pollutants in environmental samples. His work extends to metabolomics applied to aquatic organisms and the analysis of neurotoxic compounds in water systems. His research fingerprint reveals strong expertise in zebrafish models (100%), neurotransmitter analysis (66%), Daphnia magna studies (64%), and neurotoxicity assessment (21%). His recent publications (2024-2025) demonstrate a clear trend toward environmental neurotoxicology, with emphasis on the effects of pharmaceuticals and industrial pollutants on aquatic organisms. His work integrates advanced analytical techniques with biological endpoints to assess environmental risks, particularly focusing on neurological and cardiovascular impacts. The research spans method development for pollutant detection, environmental monitoring, and mechanistic studies of neurotoxic effects. Dr. Gómez Canela leads multiple significant research projects including CHEMIPARK (2024-2027) on passive sampling methodologies for environmental pollutants, GESPA (2022-2025) as part of the Environmental Process Engineering and Simulation Group, and several projects on neuroactive compounds in water systems. He has an impressive research output with 91 scientific publications from 2011-2025 and an h-index of 27 with over 2,000 citations. As a dedicated educator, he contributes to multiple academic programs including the Master in Analytical Chemistry, Master in Pharmaceutical Chemistry, and undergraduate degrees in Chemistry and Chemical Engineering. His research group GESPA represents a multidisciplinary team combining chemical engineering, biotechnology, and chemical analysis to advance environmental sustainability through theoretical and experimental approaches.
Tanya P. Garcia, PhD is an Associate Professor of Biostatistics at the Gillings School of Public Health and Research Faculty in the UNC Neurology Huntington Disease Program at the University of North Carolina at Chapel Hill . She leads the Methods for INcomplete Data (MIND) Lab , focusing on statistical methods for handling censored, missing, or incomplete data in neurodegenerative disease progression studies. Education: PhD in Statistics, Texas A&M University MS in Statistics, University of Western Ohio MS in Industrial Engineering and Operations Research, UC Berkeley Research Interests: Specializing in High-Dimensional Variable Selection , Longitudinal Data Analysis , and Neurodegenerative Disease Modeling , her work develops reproducible statistical methods for Huntington's disease progression, improving clinical trial design and biomarker identification. Scientific Awards: American Statistical Association Fellow (2024) Landis Award for Outstanding Mentorship (2024) Roy R. Kuebler Award (2024) Gertrude M. Cox Award (2024) Leadership & Mentorship: Director of the MIND Lab, Chair-Elect of the Biometrics Section of ASA, and Tyson Academic Leadership Fellow (2023–2024). Her lab alumni have secured prestigious positions at institutions like Wake Forest University and Baylor University.
Angela D. Kent is a Professor in the Department of Natural Resources and Environmental Sciences at the University of Illinois Urbana-Champaign, where she also serves as Director of the Program in Ecology, Evolution, and Conservation Biology within the School of Integrative Biology. She is affiliated with the Carl R. Woese Institute for Genomic Biology. Her research focuses on microbial communities in agroecosystems and natural environments, particularly their roles in nitrogen cycling, soil health, and sustainable bioenergy production. Key research interests include microbial interactions in plant-microbe systems, the impact of genetic variation in crops on microbial processes, and the ecological and biogeochemical implications of soil microbiomes. She has authored over 99 publications and supervised datasets on topics such as denitrification dynamics, rhizosphere microbiome assembly, and microbial contributions to nitrogen retention. Dr. Kent has received the NACTA Educator Award (2012) and has contributed to high-impact studies on topics like microbial community responses to environmental stressors and the application of stable isotopes in bioenergy research. Her work bridges microbial ecology, agronomy, and environmental science, emphasizing practical solutions for sustainable agriculture and ecosystem management.
John P. O'Doherty serves as the Fletcher Jones Professor of Decision Neuroscience within Caltech's Division of Humanities and Social Sciences, holding continuous faculty appointments since 2004 (Assistant Professor 2004-07, Associate Professor 2007-09, Professor 2009-present, Fletcher Jones Professor 2021-present). He previously directed the Caltech Brain Imaging Center (2013-17) and maintains affiliations with the T&C Chen Center for Social and Decision Neuroscience. His educational background includes a B.A. from University of Dublin, Trinity College (1996) and D.Phil. from University of Oxford (2000). His research focuses on computational and neural mechanisms of reward-based learning and decision-making , employing fMRI, intracranial recordings, and mathematical modeling to investigate how the brain solves complex decision problems through evolutionarily conserved algorithms. Key areas include Reinforcement learning systems (model-based/model-free arbitration) Observational and social learning mechanisms Neural representation of value, risk, and uncertainty Computational phenotyping of mental disorders Temporal dynamics of goal persistence Analysis of his 2023-2025 publications reveals dominant trends in computational psychiatry (problem gambling, autism traits), hierarchical decision-making, and neuroeconomic modeling of social behavior. His work consistently integrates cross-species computational frameworks with human neuroimaging to identify transdiagnostic mechanisms. While specific awards beyond his endowed professorship aren't detailed, his leadership as Brain Imaging Center Director and prolific high-impact publications demonstrate significant recognition. Current advising includes graduate researcher Sneha Aenugu on goal-persistence projects, with administrative support from Mary A. Martin (mmartin@caltech.edu). His active research program continues to pioneer computational approaches to understanding decision pathologies.
Kelly Arnold is an Associate Professor in the Department of Biomedical Engineering at the University of Michigan. Her research integrates systems engineering principles with immunology to investigate variability in immune responses across infection, vaccination, and injury, with a focus on computational modeling and clinical translation. Research Focus Systems-level immune response modeling Vaccination and antibody functionality Vaginal microbiome-host interactions Chronic lung disease progression Computational serology and proteomics Recent Work Her 2025 studies examine SARS-CoV-2 vaccination responses in cancer patients and computational frameworks for vaginal probiotics. Earlier works (2024-2007) span COPD progression, lupus fibrosis, HIV susceptibility, and tissue engineering for fertility preservation. Methodologies include proteomic profiling, network modeling, and microfluidic systems.
Dr. Chandranath Adak is an Assistant Professor at the Department of Computer Science and Engineering, Indian Institute of Technology Patna (IIT Patna), and concurrently serves as a Visiting Fellow at the School of Computer Science, University of Technology Sydney (UTS), Australia. He holds a Ph.D. in Analytics from UTS (2019) and previously served as an Assistant Professor at Indian Institute of Information Technology Lucknow (IIITL) and the Centre for Data Science at JIS Institute of Advanced Studies, Kolkata. Education: Ph.D. (Analytics), University of Technology Sydney (2019) M.Tech., Computer Science and Engineering, University of Kalyani (2014) B.Tech., Computer Science and Engineering, West Bengal University of Technology (2012) Research Interests: His work spans Computer Vision, Deep Learning, Reinforcement Learning, Document Image Analysis, and AI-driven solutions for healthcare, forensics, and industrial automation. He has pioneered methods in biomarker detection using electrochemical sensors combined with ML models, handwriting analysis for educational and forensic applications, and anomaly detection in industrial systems. His research bridges theoretical advances with real-world applications, such as medical diagnostics and quality control systems. Publications: His recent work includes innovations in biosensor-based medical diagnostics, handwriting evaluation systems, and transformer networks for historical document analysis. These contributions reflect a focus on interdisciplinary applications of AI across healthcare, cultural heritage preservation, and industrial automation. Awards: Start-up Research Grant, SERB, India (2022) Dr. Kalam Doctoral Scholarship, UTS (2018) IEEE CIS Graduate Student Research Grant (2017) Senior Member, IEEE (2024) Teaching & Supervision: Taught courses at UTS including 'Introduction to Data Analytics' and supervised research in machine learning and computer vision. His mentorship emphasizes hands-on experience with AI tools and real-world problem-solving. Labs & Teams: Engaged in collaborative projects at UTS's CIBCI Centre and Griffith University's IIIS, focusing on computational intelligence and sensor-driven AI systems.
Karsten Borgwardt is a Professor and Director of the Department of Machine Learning and Systems Biology at the Max Planck Institute of Biochemistry. He holds a PhD in Computer Science (2007) from LMU Munich and has held academic positions at ETH Zürich, Universität Tübingen, and the Max Planck Institutes in Tübingen. His research focuses on machine learning applications in biology and medicine, including biomarker discovery, personalized medicine, and systems biology. Education: PhD in Computer Science (2007), LMU Munich M.Sc. in Biology (2003), University of Oxford Diplom (M.Sc. equivalent) in Computer Science (2004), LMU Munich Research Interests: Development of machine learning algorithms for large biomedical datasets Pattern recognition in genomic and clinical data Applications in sepsis biomarkers, antimicrobial resistance prediction, and personalized medicine Grants & Projects: Scientific Coordinator of Marie Curie Networks (2013-2022) Swiss National Science Foundation Starting Grant (2014) Personalized Swiss Sepsis Study (CHF 5.3M, 2018) Awards: Krupp Award (2013), Golden Owl Teaching Award (2017), multiple 'Top 40 under 40' recognitions (2014-2016). Labs: Leads the Machine Learning and Systems Biology Department at MPI, collaborating with 22+ labs in sepsis research and international networks.
Christopher M. Overall is a Full Professor at the University of British Columbia in the Faculty of Dentistry, Department of Oral Biological and Medical Sciences . He is also a Principal Scientist at the Centre for Blood Research and holds associate memberships in UBC's Biochemistry & Molecular Biology , Obstetrics and Gynecology , and Bioinformatics Graduate Program departments. As a Canada Research Chair Laureate , he pioneered the field of degradomics to study proteases in vivo. B.D.S., University of Adelaide Ph.D., University of Toronto Postdoctoral Fellowship, UBC (with Nobel Laureate Michael Smith) Dr. Overall’s research focuses on protease proteomics and systems biology , particularly degradomics to analyze protease substrates in diseases like COVID-19 and immunodeficiency . His work on matrix metalloproteinases has revealed new therapeutic strategies for inflammatory diseases and cancer . His 15 most recent articles (2015–2008) demonstrate expertise in TAILS proteomics , protein terminomics , and protease network analysis with applications in arthritis , antiviral immunity , and precision medicine . Scientific Awards 2022 Helmut Holzer Award 2018 Royal Society of Canada Fellow 2014 Tony Pawson Canadian Proteomics Award 2013 IADR Distinguished Scientist Award Dr. Overall has mentored 61 trainees , including 9 full professors with department chairs, and received the UBC John McNeill Mentorship Award (2023). He leads the HUPO Chromosome-centric Human Proteome Project and consults for Genentech and Novartis .
Manuel R. Amieva is a Professor at Stanford University School of Medicine , holding joint appointments in Pediatrics - Infectious Diseases and Microbiology & Immunology . He is also a member of the Maternal & Child Health Research Institute (MCHRI) . His clinical practice at Stanford Medicine Children's Health focuses on pediatric infectious diseases. Education: Medical Education: Stanford University School of Medicine (1997) Fellowship: Stanford University Pediatric Infectious Disease Fellowship (2004) Internship & Residency: Stanford Health Care at Lucile Packard Children's Hospital (1998-1999) Dr. Amieva's research investigates host-pathogen interactions at epithelial barriers, with specific expertise in Helicobacter pylori , Listeria monocytogenes , Salmonella enterica , and Staphylococcus aureus . His lab develops innovative organoid culture systems with controlled polarity to study microbial colonization and oncogenic mechanisms. Key discoveries include: H. pylori's manipulation of epithelial junctions via the CagA protein Listeria's exploitation of cell extrusion sites for invasion Staphylococcus toxin interactions with adherens junctions Gastric stem cell activation by pathogens Recent publication trends show continued leadership in infectious disease mechanisms (2020-2025), with a focus on: Pathogen-specific epithelial breach strategies Organoid modeling of viral/bacterial interactions Redox-dependent host factor regulation Single-cell spatial transcriptomic analyses Multi-institutional educational frameworks His scientific collaborations span disciplines including: Gastric cancer genomics initiatives COVID-19 lung infection models Stem cell-microbe interactions Medical education reform projects Dr. Amieva maintains active clinical research while mentoring students in both the Microbiology & Immunology and Pediatrics programs. His lab at Stanford employs advanced 3D confocal microscopy and organ-on-a-chip technologies to visualize epithelial colonization dynamics.
